BioXcel Therapeutics (FRA:BX2) Debt-to-Asset : 1.24 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Debt-to-Asset?

BioXcel Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. BioXcel Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €93.82 Mil. BioXcel Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €75.74 Mil. BioXcel Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 1.24.

BioXcel Therapeutics Debt-to-Asset Historical Data

The historical data trend for BioXcel Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Debt-to-Asset Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

0.46

1.38

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.53	0.70	0.99	1.38	1.24

Competitive Comparison of BioXcel Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, BioXcel Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Debt-to-Asset falls into.

BioXcel Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioXcel Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.317	+	92.652)	/	67.585
	=	1.38

BioXcel Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	93.824)	/	75.737
	=	1.24

BioXcel Therapeutics (FRA:BX2) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioXcel Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines